14 results · 24ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

LenSX Laser System

FDA 510(k)
FDA Class 2 ·Ophthalmic

CoRoent

FDA UDI
Nuvasive, Inc.·00887517566898·CoRoent Ant TLIF PEEK, 16x11x28mm 8°

AUTO SUTURE ENDO CLIP III 5 MM CLIP APPLIER

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

STAXX XD SYSTEM

FDA 510(k)
FDA Class 2 ·Orthopedic

UNKNOWN

FDA Adverse Event
Injury ·COOK INC·Product code DTK·February 19, 2019

OT VERIO IQ METER

FDA Adverse Event
Malfunction ·LIFESCAN EUROPE, A DIVISION OF CILAG GMBH INTL·Product code NBW·June 11, 2013

FINELINE II

FDA Adverse Event
Injury ·CPI - DEL CARIBE·Product code NVN·July 13, 2011

STARCLOSE VASCULAR CLOSURE SYSTEM

FDA Adverse Event
Injury ·ABBOTT VASCULAR - REDWOOD CITY·Product code MGB·September 15, 2008

DTK FILTER, INTRAVASCULAR, CARDIOVASCULAR

FDA Adverse Event
Injury ·COOK INC·Product code DTK·February 19, 2019

UNKNOWN

FDA Adverse Event
Injury ·COOK INC·Product code DTK·February 19, 2019

UNKNOWN

FDA Adverse Event
Injury ·COOK INC·Product code DTK·February 19, 2019

MEDISLIM

FDA Adverse Event
Injury ·MEDICREATIONS, LLC·Product code GEX·April 27, 2020

UNKNOWN

FDA Adverse Event
Injury ·COOK INC·Product code DTK·March 23, 2018

Marathon Flow Directed Micro Catheter, UltraFlow HPC Flow Directed Micro Catheter Marathon Flow: The device is intended to access periphera and neurovasculature for the controlled selective infusion of physician-specified therapeutics agents such as embolization materials and of diagnostic materials such as contrast media. UltraFlow HPC Flow: The device is intended for the controlled selective infusion of physician-specified pharmacologic agents or contrast media into the distal vasculature of the peripheral and neuroanatomy. It is not intended for use in the coronary vasculature. Catalog No. 105-5055V02 105-5055V02 105-5055V05 105-5065V02 105-5065V05 105-5066V02 105-5066V05

FDA Enforcement
Class I ·Terminated·Micro Therapeutics Inc, Dba Ev3 Neurovascular·November 16, 2016